![Joseph A. Markey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph A. Markey
Keine laufenden Positionen mehr
Karriereverlauf von Joseph A. Markey
Ehemalige bekannte Positionen von Joseph A. Markey
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Verwaltungsdirektor | - | 01.11.2006 |
Finanzdirektor/CFO | - | 01.11.2006 |
Ausbildung von Joseph A. Markey
University of Scranton | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Chief Administrative Officer | 1 |
Director of Finance/CFO | 1 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
- Börse
- Insiders
- Joseph A. Markey
- Erfahrung